1. Argent BioPharma collaborates with SINTEF on antimicrobial therapies. 2. Nano-encapsulation technology aims to enhance drug efficacy for chronic wounds. 3. Advanced wound care market projected to exceed $15 billion by 2030. 4. Research targets antibiotic resistance and biofilm-related complications. 5. Innovative solutions and strategic goals set to transform wound management.
The growing wound care market aligns with Argent's innovative approach, potentially boosting RGTLF.
The projected market growth and strategic developments suggest strong future performance for RGTLF.
Projected market growth suggests RGTLF may have sustained benefits over time.
PERTH, Australia, Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.
SINTEF, headquartered in Trondheim, Norway, is an independent research organization founded in 1950 that conducts contract research and development projects.
In the project's first phase, Argent BioPharma identified SWF as the most suitable medium for testing antimicrobial efficacy in chronic wound infections. Multiple APIs were screened, revealing promising candidates whose antimicrobial activity is pH-dependent, informing future formulation strategies.
The next phase will refine API combinations for nano-encapsulation and conduct Minimum Inhibitory Concentration (MIC) studies to evaluate synergistic antimicrobial effects. This research aims to develop solutions for persistent infections, biofilm-related complications, and antibiotic resistance.
With the advanced wound care market projected to exceed $15 billion globally by 2030, Argent BioPharma's nano-medicine-driven approach is positioned to transform wound management. The company aims to improve healing outcomes, reduce antibiotic dependency, and expand into oncologic wound care, particularly for post-surgical wounds in NMSC patients.
Argent BioPharma remains committed to developing innovative therapeutic solutions for unmet medical needs.
Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
[email protected]
Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
[email protected]
SOURCE Argent BioPharma Ltd.